Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model
PLOS One · 15.04.2026 · 21 (4) · e0347205
DOI: 10.1371/journal.pone.0347205 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 15.04.2026. Verfasst von Yo Shimazu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Influenza in Birds, Triazines, Antiviral Agents, Dibenzothiepins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Environmental Restoration and Conservation Agency, Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
High pathogenicity avian influenza virus (HPAIV) infections have been frequently reported in wild birds since 2020. Because HPAIV infection has occasionally caused outbreaks in captive rare birds, treatment using antiviral drugs has been considered from the perspective of conservation medicine. In this study, the therapeutic efficacy of baloxavir marboxil (BXM) was evaluated using a duck model to support the establishment of post-infection strategies for captive avian species. Sixteen four-week-old ducks were divided into four groups and intranasally inoculated with the HPAIV strain, A/crow/Hokkaido/0103B065/2022 (H5N1). BXM was administered orally once daily at doses of 12.5, 2.5, 0.5, or 0 mg/kg to each of the four groups from 2 to 6 days post-infection. Blood samples were collected at 2, 8, and 24 hours after the initial BXM administration to measure the plasma concentrations of its active form, baloxavir acid (BXA). All ducks were monitored until 14 days post-infection, and oral and cloacal swabs were collected for virus recovery. All eight ducks administered either 12.5 or 2.5 mg/kg of BXM survived, demonstrating a significant reduction in virus recovery compared with the 0 mg/kg group. To further characterize the relationship between BXA exposure and virus shedding, an additional experiment was conducted in which ducks received a single oral administration of BXM at doses of 7.3, 4.3, or 0.5 mg/kg at 2 days post-infection. Pharmacokinetic/pharmacodynamic analysis of BXA across all dose groups showed that reductions in virus shedding from oral swabs were positively correlated with BXA exposure, and AUC 0–24hr exhibited the strongest association. These findings demonstrate that BXM administration within 48 hours post-HPAIV infection in ducks effectively reduces mortality and virus shedding. Comparison of pharmacokinetic parameters may facilitate the estimation of optimal BXM dosing options for captive avian species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- One Health Research Center, Hokkaido University, Sapporo, Hokkaido, Japan.
- International Institute for Zoonosis Control, Hokkaido University, Sapporo, Hokkaido, Japan.
- Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Hokkaido, Japan.
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
- Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
ORCID-Profile: Daiki Kobayashi, Takao Shishido, Yoshihiro Sakoda
Förderung
- Environmental Restoration and Conservation Agency
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Science and Technology Agency
Zitieren
APA
Shimazu, Y., Isoda, N., Hiono, T., Hew, Y. L., Kobayashi, D., Shibazaki, M., Nguyen, B. L., Morita, T., Obara, R. D., Miki, M., Osaki, H., Shishido, T., Ikenaka, Y., & Sakoda, Y. (2026). Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model. PLOS One, 21(4), e0347205. https://doi.org/10.1371/journal.pone.0347205
Vancouver
Shimazu Y, Isoda N, Hiono T, Hew YL, Kobayashi D, Shibazaki M, et al. Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model. PLOS One. 2026;21(4):e0347205. doi:10.1371/journal.pone.0347205
BibTeX
@article{Shimazu2026,
author = {Shimazu, Yo and Isoda, Norikazu and Hiono, Takahiro and Hew, Yik Lim and Kobayashi, Daiki and Shibazaki, Misato and Nguyen, Bao Linh and Morita, Tatsuru and Obara, Ryo Daniel and Miki, Mariko and Osaki, Hiromi and Shishido, Takao and Ikenaka, Yoshinori and Sakoda, Yoshihiro},
title = {Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0347205},
doi = {10.1371/journal.pone.0347205}
}
EUVIMED